☰

Matthew Grimmer - Publications

Affiliations: 
University of California, San Francisco, San Francisco, CA 
Tree Info Similar researchers PubMed Report error

20/30 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2020 Jones LE, Hilz S, Grimmer MR, Mazor T, Najac C, Mukherjee J, McKinney A, Chow T, Pieper RO, Ronen SM, Chang SM, Phillips JJ, Costello JF. Patient-derived cells from recurrent tumors that model the evolution of -mutant glioma. Neuro-Oncology Advances. 2: vdaa088. PMID 32904945 DOI: 10.1093/noajnl/vdaa088  0.375
2020 Oberheim Bush NA, Yu Y, Villanueva-Meyer J, Grimmer M, Hilz S, Solomon D, Choi S, Mazor T, Hong C, Shai A, Phillips JJ, McDermott M, Haas-Kogan DA, Taylor J, Butowski NA, et al. Temozolomide-induced hypermutation is associated with high-grade transformation, distant recurrence, and reduced survival after transformation in initially low-grade IDH-mutant diffuse gliomas. Journal of Clinical Oncology. 38: 2506-2506. DOI: 10.1200/Jco.2020.38.15_Suppl.2506  0.376
2020 Yu Y, Villanueva-Meyer J, Chang S, Grimmer M, Hilz S, Solomon D, Choi S, Wahl M, Mazor T, Hong C, Shai A, Phillips J, McDermott M, Haas-Kogan D, Taylor J, et al. PATH-12. TEMOZOLOMIDE-INDUCED HYPERMUTATION IS ASSOCIATED WITH HIGH-GRADE TRANSFORMATION, DISTANT RECURRENCE AND REDUCED SURVIVAL IN INITIALLY LOW GRADE IDH-MUTANT GLIOMAS Neuro-Oncology. 22: ii166-ii166. DOI: 10.1093/neuonc/noaa215.694  0.328
2019 Zhang M, Hilz S, Martin M, Hong C, Yu Y, Bollam S, Grimmer M, Looney T, Lowman G, Ganpule G, Phillips J, Shai A, Chang S, Clarke J, Taylor J, et al. IMMU-11. SPATIOTEMPORAL IMMUNOGENOMIC ANALYSIS OF THE T-CELL REPERTOIRE IN IDH-MUTANT LOWER GRADE GLIOMAS Neuro-Oncology. 21: vi121-vi121. DOI: 10.1093/Neuonc/Noz175.505  0.362
2019 Mathur R, Zhang Y, Grimmer M, Hong C, Berger M, Molinaro A, Ann Oberheim-Bush N, Chang S, Costello J. GENE-35. MGMT PROMOTER METHYLATION IN NEWLY DIAGNOSED LGG AS A POTENTIAL BIOMARKER FOR TMZ-ASSOCIATED HYPERMUTATION AT RECURRENCE Neuro-Oncology. 21: vi105-vi105. DOI: 10.1093/Neuonc/Noz175.437  0.41
2018 Choi S, Yu Y, Grimmer MR, Wahl M, Chang SM, Costello JF. Temozolomide-associated Hypermutation in Gliomas. Neuro-Oncology. PMID 29452419 DOI: 10.1093/Neuonc/Noy016  0.317
2018 Grimmer MR. Abstract LB-376: Clinico-genomic analysis of temozolomide-induced hypermutation in both molecular subtypes of IDH-mutant glioma Cancer Research. 78. DOI: 10.1158/1538-7445.Am2018-Lb-376  0.439
2018 Yu Y, Hilz S, Grimmer M, Solomon D, Choi S, Wahl M, Mazor T, Hong C, Shai A, J Phillips J, Villanueva-Meyer J, McDermott M, Haas-Kogan D, Taylor J, Butowski N, et al. PATH-29. CLINICAL SIGNIFICANCE OF TEMOZOLOMIDE-INDUCED SOMATIC HYPERMUTATION IN INITIALLY LOW-GRADE IDH-MUTANT DIFFUSE GLIOMAS Neuro-Oncology. 20: vi164-vi165. DOI: 10.1093/Neuonc/Noy148.685  0.305
2017 Campbell BB, Light N, Fabrizio D, Zatzman M, Fuligni F, de Borja R, Davidson S, Edwards M, Elvin JA, Hodel KP, Zahurancik WJ, Suo Z, Lipman T, Wimmer K, Kratz CP, ... ... Grimmer MR, et al. Comprehensive Analysis of Hypermutation in Human Cancer. Cell. PMID 29056344 DOI: 10.1016/J.Cell.2017.09.048  0.337
2015 Cage TA, Chanthery Y, Chesler L, Grimmer M, Knight Z, Shokat K, Weiss WA, Gustafson WC. Downregulation of MYCN through PI3K Inhibition in Mouse Models of Pediatric Neural Cancer. Frontiers in Oncology. 5: 111. PMID 26029667 DOI: 10.3389/Fonc.2015.00111  0.541
2015 Cage TA, Chanthery Y, Chesler L, Grimmer M, Knight Z, Shokat K, Weiss WA, Gustafson WC. Downregulation of MYCN through PI3K inhibition in mouse models of pediatric neural cancer Frontiers in Oncology. 5. DOI: 10.3389/fonc.2015.00111  0.447
2015 Mazor T, Johnson BE, Grimmer M, Hong C, Hamilton EG, Jones LE, Xavier-Magalhães A, Smirnov IV, Bengtsson H, Olshen AB, Petrecca K, Bollen AW, Berger MS, Taylor BS, Nelson SJ, et al. GENO-25HYPERMUTATION AND MALIGNANT PROGRESSION IN AN EXPANDED COHORT OF TEMOZOLOMIDE-TREATED LOW-GRADE GLIOMA PATIENTS Neuro-Oncology. 17: v97.1-v97. DOI: 10.1093/Neuonc/Nov215.25  0.432
2012 Swartling FJ, Savov V, Persson AI, Chen J, Hackett CS, Northcott PA, Grimmer MR, Lau J, Chesler L, Perry A, Phillips JJ, Taylor MD, Weiss WA. Distinct neural stem cell populations give rise to disparate brain tumors in response to N-MYC. Cancer Cell. 21: 601-13. PMID 22624711 DOI: 10.1016/J.Ccr.2012.04.012  0.554
2012 Chanthery YH, Gustafson WC, Itsara M, Persson A, Hackett CS, Grimmer M, Charron E, Yakovenko S, Kim G, Matthay KK, Weiss WA. Paracrine signaling through MYCN enhances tumor-vascular interactions in neuroblastoma. Science Translational Medicine. 4: 115ra3. PMID 22218692 DOI: 10.1126/scitranslmed.3002977  0.587
2011 Swartling FJ, Persson AI, Lau J, Northcott PA, Grimmer MR, Chesler L, Perry A, Phillips JJ, Taylor MD, Weiss WA. Abstract 3451: Interactions between N-myc and Sox9 promote medulloblastoma and determine cell fate decisions in cerebellar neural stem cells Cancer Research. 71: 3451-3451. DOI: 10.1158/1538-7445.Am2011-3451  0.554
2010 Swartling FJ, Grimmer MR, Hackett CS, Northcott PA, Fan QW, Goldenberg DD, Lau J, Masic S, Nguyen K, Yakovenko S, Zhe XN, Gilmer HC, Collins R, Nagaoka M, Phillips JJ, et al. Pleiotropic role for MYCN in medulloblastoma. Genes & Development. 24: 1059-72. PMID 20478998 DOI: 10.1101/Gad.1907510  0.586
2008 Chesler L, Goldenberg DD, Collins R, Grimmer M, Kim GE, Tihan T, Nguyen K, Yakovenko S, Matthay KK, Weiss WA. Chemotherapy-induced apoptosis in a transgenic model of neuroblastoma proceeds through p53 induction. Neoplasia (New York, N.Y.). 10: 1268-74. PMID 18953436 DOI: 10.1593/Neo.08778  0.572
2008 Grimmer MR, Weiss WA. BMPs oppose Math1 in cerebellar development and in medulloblastoma. Genes & Development. 22: 693-9. PMID 18347086 DOI: 10.1101/Gad.1657808  0.521
2007 Chesler L, Goldenberg DD, Seales IT, Satchi-Fainaro R, Grimmer M, Collins R, Struett C, Nguyen KN, Kim G, Tihan T, Bao Y, Brekken RA, Bergers G, Folkman J, Weiss WA. Malignant progression and blockade of angiogenesis in a murine transgenic model of neuroblastoma. Cancer Research. 67: 9435-42. PMID 17909053 DOI: 10.1158/0008-5472.Can-07-1316  0.597
2006 Grimmer MR, Weiss WA. Childhood tumors of the nervous system as disorders of normal development. Current Opinion in Pediatrics. 18: 634-8. PMID 17099362 DOI: 10.1097/Mop.0B013E32801080Fe  0.541
Low-probability matches (unlikely to be authored by this person)
2021 Yu Y, Villanueva-Meyer J, Grimmer MR, Hilz S, Solomon DA, Choi S, Wahl M, Mazor T, Hong C, Shai A, Phillips JJ, Wainer BH, McDermott M, Haas-Kogan D, Taylor JW, et al. Temozolomide-induced hypermutation is associated with distant recurrence and reduced survival after high-grade transformation of low-grade IDH-mutant gliomas. Neuro-Oncology. PMID 33823014 DOI: 10.1093/neuonc/noab081  0.289
2017 Jones L, Mazor T, Grimmer M, Najac C, Mukherjee J, Chow T, Pieper R, Ronen S, Phillips JJ, Chang S, Costello J. TMOD-23. ESTABLISHMENT AND CHARACTERIZATION OF IDH1-MUTANT HYPERMUTATED GLIOMA CELL LINES Neuro-Oncology. 19: vi259-vi259. DOI: 10.1093/Neuonc/Nox168.1060  0.289
2020 Mathur R, Zhang Y, Grimmer MR, Hong C, Zhang M, Bollam S, Petrecca K, Clarke J, Berger MS, Phillips JJ, Oberheim-Bush NA, Molinaro AM, Chang SM, Costello JF. MGMT promoter methylation level in newly diagnosed low-grade glioma is a predictor of hypermutation at recurrence. Neuro-Oncology. PMID 32166314 DOI: 10.1093/Neuonc/Noaa059  0.27
2019 Barthel FP, Johnson KC, Varn FS, Moskalik AD, Tanner G, Kocakavuk E, Anderson KJ, Abiola O, Aldape K, Alfaro KD, Alpar D, Amin SB, Ashley DM, Bandopadhayay P, Barnholtz-Sloan JS, ... ... Grimmer MR, et al. Longitudinal molecular trajectories of diffuse glioma in adults. Nature. PMID 31748746 DOI: 10.1038/S41586-019-1775-1  0.241
2015 Grimmer MR, Costello JF. Cancer: Oncogene brought into the loop. Nature. PMID 26700812 DOI: 10.1038/Nature16330  0.189
2014 Grimmer MR, Farnham PJ. Can genome engineering be used to target cancer-associated enhancers? Epigenomics. 6: 493-501. PMID 25431942 DOI: 10.2217/Epi.14.30  0.18
2016 Tak YG, Hung Y, Yao L, Grimmer MR, Do A, Bhakta MS, O'Geen H, Segal DJ, Farnham PJ. Effects on the transcriptome upon deletion of a distal element cannot be predicted by the size of the H3K27Ac peak in human cells. Nucleic Acids Research. PMID 26743005 DOI: 10.1093/Nar/Gkv1530  0.17
2022 Marei H, Tsai WK, Kee YS, Ruiz K, He J, Cox C, Sun T, Penikalapati S, Dwivedi P, Choi M, Kan D, Saenz-Lopez P, Dorighi K, Zhang P, Kschonsak YT, ... ... Grimmer M, et al. Antibody targeting of E3 ubiquitin ligases for receptor degradation. Nature. PMID 36131013 DOI: 10.1038/s41586-022-05235-6  0.148
2014 Grimmer MR, Stolzenburg S, Ford E, Lister R, Blancafort P, Farnham PJ. Analysis of an artificial zinc finger epigenetic modulator: widespread binding but limited regulation. Nucleic Acids Research. 42: 10856-68. PMID 25122745 DOI: 10.1093/Nar/Gku708  0.109
2022 de Mendoza A, Nguyen TV, Ford E, Poppe D, Buckberry S, Pflueger J, Grimmer MR, Stolzenburg S, Bogdanovic O, Oshlack A, Farnham PJ, Blancafort P, Lister R. Large-scale manipulation of promoter DNA methylation reveals context-specific transcriptional responses and stability. Genome Biology. 23: 163. PMID 35883107 DOI: 10.1186/s13059-022-02728-5  0.086
Hide low-probability matches.